nor-Binaltorphimine dihydrochloride: Selective κ-Opioid Receptor Antagonist for Signal Transduction Studies

Executive Summary: nor-Binaltorphimine dihydrochloride (SKU B6269, APExBIO) is a highly selective κ-opioid receptor antagonist used in research to elucidate opioid receptor-mediated signal transduction (APExBIO). It exhibits a molecular weight of 734.72 and a chemical formula of C₄₀H₄₃N₃O₆·2HCl, with solubility <18.37 mg/mL in DMSO. nor-Binaltorphimine dihydrochloride enables researchers to isolate κ-opioid receptor functions in pain and addiction studies (Huo et al., 2023). It is supplied at 98.00% purity and should be stored at -20°C for maximal stability. This compound is intended strictly for research use and not for clinical applications (APExBIO).

Biological Rationale

κ-opioid receptors (KORs) play a central role in modulating pain, stress response, and reward pathways. Activation of KORs in the spinal dorsal horn regulates mechanical allodynia, a hallmark of chronic pain syndromes (Huo et al., 2023). Selective antagonists like nor-Binaltorphimine dihydrochloride allow for specific inhibition of KOR-mediated pathways, facilitating mechanistic studies in neurobiology and pharmacology. Understanding KOR signaling is crucial for the development of non-addictive analgesics and the elucidation of opioid receptor crosstalk in pain and addiction circuits (internal review).

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride acts as a highly selective and potent antagonist at κ-opioid receptors. Upon administration in vitro or in vivo, it binds to the KOR with high affinity, competitively inhibiting endogenous ligands such as dynorphins (Huo et al., 2023). This blockade prevents KOR-mediated G-protein signaling, including inhibition of adenylyl cyclase and downstream effects on neuronal excitability. Selectivity for KOR over μ- and δ-opioid receptors is a key feature, enabling targeted studies of KOR-specific pathways. The compound’s action is reversible and dose-dependent, with rapid onset in experimental models (detailed extension).

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride blocks spinal KORs, leading to persistent bilateral mechanical allodynia in mice when administered intrathecally (Huo et al., 2023, DOI).
• It demonstrates >100-fold selectivity for KOR over μ- and δ-opioid receptors in radioligand binding assays (product documentation, APExBIO).
• In rodent models, nor-Binaltorphimine dihydrochloride (1–10 mg/kg, i.p.) produces dose-dependent antagonism of KOR agonist-induced antinociception with negligible effect on μ-opioid responses (see Table 2, Huo et al., 2023).
• Analyses confirm compound purity ≥98% by HPLC and stability under -20°C storage for at least 12 months (manufacturer’s QC, APExBIO).
• Solutions in DMSO remain active for <48 hours at 4°C, with loss of potency observed in extended storage (>48 hours) (stability notice, APExBIO).

Applications, Limits & Misconceptions

nor-Binaltorphimine dihydrochloride is instrumental in:

• Dissecting κ-opioid receptor-mediated pain modulation and the underlying neural circuits (internal article; this article expands on mechanistic findings and translational implications).
• Studying opioid receptor cross-talk in addiction, stress, and reward pathways.
• Screening drug candidates for KOR selectivity in pharmacological assays.
• Validating hypotheses on KOR involvement in chronic and neuropathic pain (internal Q&A resource; this article provides updated laboratory benchmarks and troubleshooting guidance).

Common Pitfalls or Misconceptions

• nor-Binaltorphimine dihydrochloride does not antagonize μ- or δ-opioid receptors at standard research concentrations (see selectivity data).
• It is not intended or validated for clinical or diagnostic use.
• Long-term storage of solutions, even at -20°C, leads to loss of antagonist potency.
• Off-target effects can occur at supraphysiological concentrations (>50μM).
• Vehicle choice (DMSO) may affect solubility; aqueous buffers are unsuitable for stock solutions.

Workflow Integration & Parameters

For opioid receptor pharmacology or pain modulation research:

• Reconstitute nor-Binaltorphimine dihydrochloride in DMSO at concentrations up to 18.37 mg/mL. Avoid water or PBS for stock solutions.
• Aliquot and store at -20°C. Use within 48 hours of dilution for optimal activity.
• For in vivo studies, typical dosing is 1–10 mg/kg (i.p. or i.t.), depending on the species and assay endpoints (APExBIO product sheet).
• Shipping on blue ice is recommended to maintain integrity during transit.
• Include controls for vehicle and off-target opioid receptor antagonism in all experiments.

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride, as provided by APExBIO, is a cornerstone reagent for selective κ-opioid receptor antagonist assays and opioid receptor-mediated signal transduction studies. Its high selectivity, documented stability, and robust performance underpin its value in pain modulation and addiction circuit research. Ongoing advances in neural circuit mapping and pharmacological interrogation will further leverage this compound for translational pain and addiction research (internal review update; this article clarifies use parameters and links to recent circuit-level findings). For details on sourcing and technical specifications, refer to the official nor-Binaltorphimine dihydrochloride product page.